Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine combined with remimazolam for anesthesia in ambulatory hysteroscopic surgery
ChiCTR2200065518Phase 4Completed
- Sponsor
- Weifang Maternal and Child Health Care Hospital
- Start
- Nov 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nalbuphine, remimazolam and propofol in hysteroscopic surgery (3 arms), sponsored by Weifang Maternal and Child Health Care Hospital. Primary endpoint: Total incidence of perioperative adverse events. Started Nov 2022; status: completed.
02
Drugs
nalbuphineremimazolampropofol
03
Conditions
hysteroscopic surgery
Beyond the preview
Go deeper on ChiCTR2200065518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065518.